Once in the liver, acetate is used by the lipogenic pathway through its conversion to acetyl-CoA by acetyl-CoA synthetase 2 (ACSS2), an enzyme transcriptionally controlled by ChREBP (105), reinforcing the role of ChREBP in the spectrum of NAFLD development (Figure 2). Here, MLXIPL is linked to metabolic dysfunction-associated steatotic liver disease.